Science Explorer Back to mapMap
Discussion
Researcher · Klinik Hietzing · Austria

Michael Medl

Michael Medl publishes mostly in Reproductive Medicine, Obstetrics and Gynecology and Cancer Research, on topics such as Ovarian cancer diagnosis and treatment, Breast Cancer Treatment Studies and Endometrial and Cervical Cancer Treatments.

OpenAlex
World rank
#6,863,846
of 7,710,434 ranked researchers
Rank in Austria
#40,341
of 43,330
Works
64
Citations
1.1k
Citations per work
17.7
h-index
21
i10-index 29Top 21% in Reproductive Medicine
Michael Medl

What does Michael Medl research?

Michael Medl's work is mostly in Medicine (38%), Biochemistry, Genetics and Molecular Biology (17%).

Everything else: 28 works · 44.2% of their workHealth Sciences: 25 works · 38.4% of their workMedicine: 25 works · 38.4% of their workReproductive Medicine: 8 works · 12.0% of their workObstetrics and Gynecology: 7 works · 10.8% of their workOncology: 5 works · 8.4% of their workPathology and Forensic Medicine: 5 works · 7.2% of their workLife Sciences: 11 works · 17.4% of their workBiochemistry, Genetics and Molecular Biology: 11 works · 17.4% of their workCancer Research: 6 works · 9.0% of their workMolecular Biology: 5 works · 8.4% of their workTHEIR WORKMichael Medl64works
Life Sciences17%Health Sciences38%

Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.

The fields and subfields, with their numbers
  1. Everything else2844.2%
    1. Medicine2538.4%
    1. Biochemistry, Genetics and Molecular Biology1117.4%
  1. 1Reproductive Medicine12% of their works
  2. 2Obstetrics and Gynecology11% of their works
  3. 3Cancer Research9% of their works
  4. 4Oncology8% of their works
  5. 5Molecular Biology8% of their works
  6. 6Pathology and Forensic Medicine7% of their works

Research topics

Which keywords describe Michael Medl's research?

The keywords of their largest research topics: Clinical Practice Guidelines, Survival Analysis, Metastasis, Genomic Analysis, Ovarian Cancer, Breast Tumours, Gene Expression and Breast Cancer.

Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.

All 20 words, with their numbers
  1. Clinical Practice Guidelines192 topics
  2. Survival Analysis192 topics
  3. Metastasis172 topics
  4. Genomic Analysis141 topic
  5. Ovarian Cancer141 topic
  6. Breast Tumours101 topic
  7. Gene Expression101 topic
  8. Breast Cancer91 topic
  9. Cervical Cancer91 topic
  10. Endometrial Carcinoma91 topic
  11. Mammography91 topic
  12. Angiogenesis82 topics
  13. Fibroblast Activation Protein51 topic
  14. Tumor Microenvironment51 topic
  15. Diagnosis41 topic
  16. Glycans41 topic
  17. Glycosylation41 topic
  18. Management41 topic
  19. Matrix Metalloproteinases31 topic
  20. Tissue Inhibitors of Metalloproteinases31 topic

Where does Michael Medl work?

Michael Medl's main affiliation in the publication record is Klinik Hietzing, Austria.

How many publications and citations does Michael Medl have?

OpenAlex counts 64 works and 1,133 citations for Michael Medl, an h-index of 21, ranking #6,863,846 of 7,710,434 researchers worldwide on the quality score.

Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.

Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.

Discussion

Ask a question or share a note about Michael Medl. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.